Mainz Biomed N.V. (MYNZ)
- Previous Close
3.7000 - Open
3.8700 - Bid 3.4900 x 100
- Ask 3.7900 x 100
- Day's Range
3.5500 - 4.3400 - 52 Week Range
0.1800 - 8.2000 - Volume
907,949 - Avg. Volume
268,100 - Market Cap (intraday)
10.818M - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
-- - EPS (TTM)
-22.3600 - Earnings Date Apr 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
mainzbiomed.com19
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MYNZ
View More
Performance Overview: MYNZ
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYNZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYNZ
View MoreValuation Measures
Market Cap
10.82M
Enterprise Value
7.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.86
Price/Book (mrq)
1.79
Enterprise Value/Revenue
8.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.37%
Return on Equity (ttm)
-465.82%
Revenue (ttm)
893.99k
Net Income Avi to Common (ttm)
-21.65M
Diluted EPS (ttm)
-22.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
6.24M
Total Debt/Equity (mrq)
54.10%
Levered Free Cash Flow (ttm)
-10.45M